Viking Therapeutics (VKTX) Q3 FY2025 earnings: revenue $0
Viking Therapeutics, Inc. (VKTX) reported revenue of $0 for Q3 FY2025, the quarter ended 30 September 2025. Net income was -$91 million, and diluted earnings per share $-0.81. The figures are the company's own, from the 10-Q it filed with the SEC on 23 October 2025.
Revenue$0
Net income-$91 million
Diluted EPS$-0.81
QuarterQ3 FY2025ended 30 September 2025
The quarter, against the one before and a year earlier
| Line | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | Change on the year |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | n/a |
| Research and development | 90.0 | 60.2 | 22.8 | +294.8% |
| Operating income | -98.6 | -74.6 | -36.6 | n/a |
| Net income | -90.8 | -65.6 | -24.9 | n/a |
| Diluted EPS | -$0.81 | -$0.58 | -$0.22 | n/a |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow and capital returned
| Line | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | Change on the year |
|---|---|---|---|---|
| Operating cash flow | -94.0 | -47.1 | -22.0 | n/a |
| Cash from investing | 160 | 42.5 | 25.9 | +517.8% |
| Cash from financing | 0.5 | 0.5 | 2.5 | -81.0% |
| Share-based compensation | 7.3 | 13.5 | 9.0 | -18.3% |
| Diluted shares, weighted | 112m | 112m | 111m | +1.3% |
| Shares outstanding at period end | 112m | 112m | 111m | +0.9% |
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet at quarter end
| Line | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | Change on the year |
|---|---|---|---|---|
| Shareholders' equity | 713 | 795 | 911 | -21.8% |
| Debt | 0.0 | 0.0 | 0.0 | n/a |
| Operating lease liabilities | 0.3 | 0.4 | 0.8 | -57.9% |
| Other liabilities | 26.1 | 32.0 | 25.7 | +1.5% |
| Total liabilities and equity | 739 | 828 | 938 | -21.2% |
| Investments | 614 | 774 | 880 | -30.2% |
| Cash and equivalents | 100 | 33.9 | 50.3 | +99.4% |
| Other assets | 24.8 | 20.1 | 7.4 | +233.6% |
| Total assets | 739 | 828 | 938 | -21.2% |
Questions
What was Viking Therapeutics' revenue in Q3 FY2025?
Viking Therapeutics (VKTX) reported revenue of $0 for Q3 FY2025, the quarter ended 30 September 2025.
How much did Viking Therapeutics earn in Q3 FY2025?
Net loss for Q3 FY2025 was $91 million, and the diluted loss per share $0.81.
When did Viking Therapeutics report Q3 FY2025 results?
Viking Therapeutics filed its 10-Q for the quarter ended 30 September 2025 with the SEC on 23 October 2025.
Quarterly results, the last 20 quarters
| Q3 FY2021 | Q4 FY2021 * | Q1 FY2022 | Q2 FY2022 | Q3 FY2022 | Q4 FY2022 * | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| R&D | 10.8 | 9.8 | 12.6 | 13.5 | 12.0 | 16.2 | 11.0 | 13.9 | 18.4 | 20.5 | 24.1 | 23.8 | 22.8 | 31.0 | 41.4 | 60.2 | 90.0 | 153 | 150 | 116 |
| Operating income | -13.4 | -12.5 | -16.2 | -17.6 | -16.2 | -20.3 | -20.5 | -23.7 | -27.3 | -29.3 | -34.1 | -34.1 | -36.6 | -46.2 | -55.5 | -74.6 | -98.6 | -165 | -164 | -133 |
| Net income | -13.2 | -12.4 | -16.1 | -17.4 | -15.8 | -19.6 | -19.5 | -19.2 | -22.5 | -24.6 | -27.4 | -22.2 | -24.9 | -35.4 | -45.6 | -65.6 | -90.8 | -158 | -158 | -128 |
| Diluted EPS | -$0.17 | -$0.15 | -$0.21 | -$0.23 | -$0.21 | -$0.26 | -$0.25 | -$0.19 | -$0.23 | -$0.24 | -$0.26 | -$0.20 | -$0.22 | -$0.32 | -$0.41 | -$0.58 | -$0.81 | -$1.38 | -$1.37 | -$1.10 |
| Operating cash flow | -10.9 | -12.3 | -10.5 | -13.4 | -13.5 | -10.9 | -24.6 | -11.4 | -19.7 | -17.6 | -6.1 | -28.5 | -22.0 | -31.2 | -52.3 | -47.1 | -94.0 | -85.3 | -114 | -125 |
| Buybacks | n/a | n/a | 5.1 | 1.7 | 0.0 | 0.0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | 78m | 78m | 77m | 77m | 77m | 78m | 79m | 100m | 100m | 100m | 110m | 111m | 111m | 112m | 112m | 112m | 112m | 115m | 116m | 117m |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.10-Q for the period ended 30 September 2025, filed 23 October 2025: the filing.